openPR Logo
Press release

Vascular Endothelial Growth Factor (VEGF) Antibodies Market Opportunity Analysis, 2018-2026

08-24-2018 03:19 PM CET | Health & Medicine

Press release from: Coherent Market Insights

Vascular Endothelial Growth Factor (VEGF) Antibodies Market

Vascular Endothelial Growth Factor (VEGF) is a signal protein that helps in the formation of new blood vessels through a process known as angiogenesis. Vascular endothelial growth factor is a part of several pathological processes and researches are often carried out for the development of novel therapies using these factors for diseases such as cancer. Normal functions of vascular endothelial growth factor includes embryonic development, formation of new blood vessels, and as a bypass for a blocked vessel. However, overexpression of VEGF often culminates into fatal disease such as cancerous cells. As solid tumors require additional blood supply in order to keep functioning, the overexpression of VEGF serves that purpose through angiogenesis.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1614

VEGF family has five members such as VEGF-A, VEGF-B, VEGF-C, VEGF-D, and Placenta Growth Factor (PGF). Out of these growth factors, VEGF-A is responsible for angiogenesis and processes associated with endothelial cells. VEGF-A binds to VEGF receptors on the endothelial cells, which triggers a tyrosine kinase pathway leading to angiogenesis. VEGF-A has been found to be associated with poor prognosis in various cancers, diabetic retinopathy, and age-related macular degeneration. Therapeutic agents are developed to inhibit the transduction pathways of vascular endothelial growth factor (VEGF). Drugs such as monoclonal antibodies against VEGF and tyrosine kinase inhibitors inhibit the angiogenesis process and disease progression.

Vascular Endothelial Growth Factor (VEGF) Antibodies Market Drivers

Rising prevalence of diseases such as cancer and macular degeneration is expected to boost growth of the market over the forecast period. According to the American Cancer Society, in 2017, cancer was the second most common cause of death in the U.S., which accounts for nearly 1 out of every 4 deaths. Novel therapies such as monoclonal antibodies and angiogenesis inhibitors are highly specialized targeted therapies, which directly targets the cancerous cells. The preference for targeted therapies is rising, owing to the advantages (lesser side effects) offered by targeted therapies over conventional therapies such as chemotherapy. Furthermore, robust pipeline of VEGF antibodies is expected to boost the market growth over the forecast period. For instance, Brolucizumab (Alcon) is in phase 3 clinical trials, Abicipar (Allergan Plc) is in phase 3 trials, and RG7716 (Genentech) is in phase 2 trials, all indicated for age-related macular degeneration.

Moreover, Tecentriq manufactured by Roche received the U.S. FDA priority review status to treat people with metastatic non-squamous non-small cell lung cancer in May 2018. Therapies already present in the market have shown improved clinical outcome in cancer as well as age-related macular degeneration (AMD). For instance, Lucentis, as well as Avastin have shown significant improvement in medical outcomes in associated indications such as cancer. These therapies have spurred the interest of manufacturers to further carry out research in this category, which is shown in terms of number of agents present in the pipeline. Blockbuster drugs such as Avastin and Lucentis allow manufacturers to invest in research and development of such therapies, in order to generate the revenues later on while providing the benefits to patients as well. These factors are expected to foster growth of the market over the forecast period.

However, high costs of these medications, biosimilar research, and subsequent launches are expected to hamper the growth of the market. The U.S. Food & Drug Administration has already approved Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab) in December 2017. Moreover, European Commission approved biosimilar to Avastin (bevacizumab) in January 2018.

Vascular Endothelial Growth Factor (VEGF) Antibodies Market Insights

On the basis of region, North America and Europe are expected to show significant growth in the vascular endothelial growth factor antibodies market over the forecast period. North America has the presence of leading manufacturers who are indulged in research and development of these therapies. Manufacturers such as Novartis (Europe) and Genentech have these therapies in pipeline and are expected to enter into the market over the forecast period. Asia Pacific region is expected to show modest growth, owing to high costs of these therapies and fairly low availability overall the region. Sophisticated insurance facilities such as Medicaid and Medicare are not present in the developing economies due to which patients cannot afford costly medical treatment in these regions. However, insurance facilities are expected to drive growth of the market in North America.

Access Table of Content (TOC) Of the Report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1614

Key players operating in the vascular endothelial growth factor (VEGF) antibodies market include Genentech, Inc., Novartis, Exelixis, Inc., Eli Lilly and Company, Bayer Pharma AG, Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals, Ceres Oncology Pty Ltd, and ThromboGenics, Inc.

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Vascular Endothelial Growth Factor (VEGF) Antibodies Market Opportunity Analysis, 2018-2026 here

News-ID: 1200627 • Views: 149

More Releases from Coherent Market Insights

Imortant Facts about Global Cryptocurrency ATM Market You Should Know | Leading …
Cryptocurrency ATMs are the easiest means to buy cryptocurrencies, which also support selling of the digital currencies. Owing to their capability to support multiple forms of cryptocurrencies and ability to support any national currencies across the globe, these machines have gained significant traction over the past few years. Prominent growth factor fueling demand is the proliferation of these digital assets or currencies, across the globe and growing acceptance of these
Making Potential Expansion Prospects In The Cognitive Systems Market
The cognitive system is a suit of technologies, which extracts the insights form the structured and unstructured data by using machine learning and natural language processing technology. The increasing unstructured data, such as call center transcripts, documents, email messages, social media content, and social networking sites contents has become one of the major factors for the growth of the cognitive system market. For instance, approximately 300 million photos are uploaded
A Comprehensive Study Explore How Global Outdoor LED Display Market Will Grow In …
The global outdoor LED display market is projected to reach over US$ 40 billion by 2025, exhibiting a CAGR of 9.56% over the forecast period (2017 to 2025). The Outdoor LED display market is primarily driven by the innovation and modernization offered by LED lighting systems over incandescent and fluorescent lamps. Additionally, the energy efficiency of LED lights, longer lifetime, HD resolution, good pixel, enhanced physical strength, smaller size, design
Virtual and Augmented Reality Market To Exhibit Skyrocketing Expansion with Blip …
The market report envelopes all-in information on the global Virtual and Augmented Reality Market and the nature of the market growth over the foreseeable period. The report provides a comprehensive elaboration of the positives and negatives of the global Virtual and Augmented Reality market with Regression Analysis, S.T.E.E.P.L.E and Porter's Five Forces Analysis. With SWOT analysis, the report offers detailed insights about different players operating within the Virtual and Augmented

All 5 Releases


More Releases for VEGF

Vascular Endothelial Growth Factor (VEGF) Antibodies Market By 2026 Genentech, N …
Vascular Endothelial Growth Factor (VEGF) is a signal protein that helps in the formation of new blood vessels through a process known as angiogenesis. Vascular endothelial growth factor is a part of several pathological processes and researches are often carried out for the development of novel therapies using these factors for diseases such as cancer. Normal functions of vascular endothelial growth factor includes embryonic development, formation of new blood vessels,
Vascular Endothelial Growth Factor (VEGF) Antibodies Market Trends, Outlook, and …
Vascular Endothelial Growth Factor (VEGF) is a signal protein that helps in the formation of new blood vessels through a process known as angiogenesis. Vascular endothelial growth factor is a part of several pathological processes and researches are often carried out for the development of novel therapies using these factors for diseases such as cancer. Normal functions of vascular endothelial growth factor includes embryonic development, formation of new blood vessels,
Market Insights: Anti-VEGF Drugs to Remain Preferred for Treatment of Proliferat …
Researchmoz added Most up-to-date research on "Proliferative Diabetic Retinopathy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2026" to its huge collection of research reports. Proliferative diabetic retinopathy prevails as leading cause of blindness across industrialized countries worldwide. Although remarkable advancements have been made in the diagnosis and treatment of the disease, several imperative management questions as well as treatment deficiencies continue to persist unanswered. The
Vascular Endothelial Growth Factor (VEGF) Antibodies Market Report Explored in L …
Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market: Overview Vascular endothelial growth factor is an integral part of several pathophysiological processes. This is the primary reason why it is extensively used for designing therapies to treat patients with macular degeneration and cancers. The global vascular endothelial growth factor (VEGF) antibodies is gaining momentum as it is known to be far more effective than conventional pharmaceuticals. Currently, VEGF antibodies used for treating
Global Ophthalmic Therapeutics-Drug Market By Type | Antiallergy, Anti-VEGF agen …
Researchmoz added Most up-to-date research on "Global Ophthalmic Therapeutics-Drug Market By Type | Antiallergy, Anti-VEGF agents, Anti-inflammatory and Antiglaucoma" to its huge collection of research reports. This report studies the global Ophthalmic Therapeutics/Drug market, analyzes and researches the Ophthalmic Therapeutics/Drug development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Novartis AG Allergan Santen Pharmaceutical Co., Ltd. Pfizer Inc. Merck &
Trends in the Vascular Endothelial Growth Factor (VEGF) Antibodies Market 2016 - …
Vascular endothelial growth factor is an integral part of several pathophysiological processes. This is the primary reason why it is extensively used for designing therapies to treat patients with macular degeneration and cancers. The global vascular endothelial growth factor (VEGF) antibodies is gaining momentum as it is known to be far more effective than conventional pharmaceuticals. Currently, VEGF antibodies used for treating cancer contribute more than half the total revenue